Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.
Shiller PE for Stocks: The True Measure of Stock Valuation
Globus Medical (BSP:G2ME34) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Globus Medical Cyclically Adjusted PS Ratio Related Terms
Globus Medical Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Globus Medical's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:G2ME34 vs PODD, BRKR, GKOS: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Globus Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Globus Medical's Cyclically Adjusted PS Ratio falls into.
Globus Medical Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Is Globus Medical (BSP:G2ME34) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of R$52.00 is trading 11.1% below its estimated GF Value™ of R$58.52.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for BSP:G2ME34:
Cyclically Adjusted PS Ratio:
GF Value™: R$58.52 vs. price of R$52.00 (11.1% below fair value)
No single metric tells the full story. See the BSP:G2ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
26GF Score
Get the complete analysis for BSP:G2ME34
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:G2ME34 has been successfully added to your 
